Rachel Gibson

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

V. Libri, T. Foltynie, P. Limousin, 2020, BMJ Open.

The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers

E. Tolosa, O. Rascol, G. Ebersbach, 2021, Journal of Parkinson's disease.

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study

J. Ioannidis, M. Farrer, D. Maraganore, 2011, The Lancet Neurology.

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

V. Libri, T. Foltynie, P. Limousin, 2021, BMJ Open.

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study

J. Ioannidis, M. Farrer, D. Maraganore, 2011, The Lancet Neurology.